CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty CLDF Committees 2022 GI Fellow Board of Advisors
Embassy of Education  
Slide Library Publications Webcasts Abstract Library
 
PBC Disease Content  
Publications
 
Slide Library
   Released: 2022
test
PBC: Diagnosis and Current Management Strategies
41 slides
 
 
   Released: 2020
test
Clinical Insights Into the Management of Primary Biliary Cholangitis (PBC)
53 slides
 
 
   Released: 2020
test
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current and Emerging Treatments
48 slides
 
 
 
Recorded Educational Webinar

Webcast Library
     
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current and Emerging Treatments   CME Webcast
CME eNewsletter
     
  Newsletter  
     
  Credit Designation  
  1.0 AMA PRA  
  Category 1 Credit(s)™  
  View  
  Provided by:
CLDF

Accredited by:
CLDF

This educational material was supported by an educational grant Intercept Pharmaceuticals. 		 
     
 
 
Primary Biliary Cholangitis: Diagnosis and Management
 
Target Audience
The target audience for this enduring activity is hepatologists, gastroenterologists, advanced practice registered nurses, and physician assistants who manage patients with PBC.
 
Educational Objectives
Upon completion of this activity, participants should be better able to:
• Describe evolving patient management strategies for primary biliary cholangitis (PBC)
• Discuss the latest treatment algorithms for PBC and apply them to clinical practice
 
Accreditation Statement
Please see page 1 of the newsletter for full accreditation statement.
 
 
 
 
Abstract Library
1.Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells
 

Hepatol Commun. 2023 Apr 4;7(4):e0110. doi: 10.1097/HC9.0000000000000110.eCollection 2023 Apr 1.

Victoria Mulcahy 1 2, Evaggelia Liaskou 3 4, Jose-Ezequiel Martin 1 5, Prasanti Kotagiri 6 7, Jonathan Badrock 1, Rebecca L Jones 8, Simon M Rushbrook 9, Stephen D Ryder 10, Douglas Thorburn 11, Simon D Taylor-Robinson 12, Graeme Clark 13, Heather J Cordell 14, Richard N Sandford 1, David E Jones 15 16, Gideon M Hirschfield 17, George F Mells 1 2
 
2.Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis
 

Dig Dis Sci. 2023 Apr;68(4):1559-1573. doi: 10.1007/s10620-022-07704-4.Epub 2022 Sep 30.

Nidah Shabbir Khakoo 1, Shahnaz Sultan 2, John M Reynolds 3, Cynthia Levy 4 5
 
3.Role of autoantibodies in the clinical management of primary biliary cholangitis
 

World J Gastroenterol. 2023 Mar 28;29(12):1795-1810.doi: 10.3748/wjg.v29.i12.1795.

Eirini I Rigopoulou 1 2, Dimitrios P Bogdanos 3
 
4.Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis
 

Dig Dis Sci. 2023 Feb;68(2):514-520. doi: 10.1007/s10620-022-07654-x.Epub 2022 Aug 22.

Guilherme Grossi Lopes Cançado 1 2, Cláudia Alves Couto 3, Debora Raquel Benedita Terrabuio 4, Eduardo Luiz Rachid Cançado 4, Cristiane Alves Villela-Nogueira 5, Maria Lucia Gomes Ferraz 6, Michelle Harriz Braga 4, Mateus Jorge Nardelli 3, Luciana Costa Faria 3, Nathalia Mota de Faria Gomes 6, Elze Maria Gomes Oliveira 7, Vivian Rotman 5, Maria Beatriz Oliveira 8, Simone Muniz Carvalho Fernandes da Cunha 9, Marlone Cunha-Silva 10, Liliana Sampaio Costa Mendes 11, Claudia Alexandra Pontes Ivantes 12, Liana Codes 9 13, Valéria Ferreira de Almeida E Borges 14 15, Fabio Heleno de Lima Pace 16, Mario Guimarães Pessoa 4, Laura Vilar Guedes 4, Izabelle Venturini Signorelli 17, Gabriela Perdomo Coral 18, Cynthia Levy 19, Paulo Lisboa Bittencourt 13 20; Members of the Brazilian Cholestasis Study Group Consortium
 
5.Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review
 

Dig Dis Sci. 2023 Mar 18;1-21. doi: 10.1007/s10620-023-07862-z. Online ahead of print.

Helen T Smith 1, Andrea Ribeiro de Souza 2, April H Thompson 3, Megan M McLaughlin 4, John J Dever 5, Julie A Myers 5, Jing Voon Chen 6
 
6.Pharmacological Therapy of Pruritus in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
 

Clin Gastroenterol. 2023 Feb 1;57(2):143-152.doi: 10.1097/MCG.0000000000001797.

Esli Medina-Morales 1, Romelia Barba Bernal 1, Heike Gerger 2 3, Daniela Goyes 4, Hirsh D Trivedi 1, Bryan Ferrigno 1, Vilas Patwardhan 1, Alan Bonder 1
 
7.Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial
 

Hepatol Commun. 2023 Feb 20;7(3):e0057.doi: 10.1097/HC9.0000000000000057. eCollection 2023 Mar 1.

David Jones 1, Marco Carbone 2 3, Pietro Invernizzi 2 3, Nicola Little 4, Frederik Nevens 5, Mark G Swain 6, Philippe Wiesel 7, Cynthia Levy 8
 
8.New Treatment Paradigms in Primary Biliary Cholangitis
 

Clin Gastroenterol Hepatol. 2023 Feb 19;S1542-3565(23)00110-6.doi: 10.1016/j.cgh.2023.02.005. Online ahead of print.

Cynthia Levy 1, Michael Manns 2, Gideon Hirschfield 3
 
9.Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis
 

Clin Chim Acta. 2023 Feb 1;540:117219. doi: 10.1016/j.cca.2023.117219. Epub 2023 Jan 4.

Troy D Jaskowski 1, Vijayalakshmi Nandakumar 2, Camille L Novis 1, Michael Palmer 1, Anne E Tebo 3
 
10.Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series
 

J Transl Autoimmun. 2023 Jan 14;6:100189. doi: 10.1016/j.jtauto.2023.100189. eCollection 2023.

Mirjam Kolev 1 2, Adela-Cristina Sarbu 3, Burkhard Möller 3, Britta Maurer 3, Florian Kollert 3, Nasser Semmo 1
 
11.Mechanisms of pruritus in cholestasis: understanding and treating the itch
 

Nat Rev Gastroenterol Hepatol. 2023 Jan;20(1):26-36.doi: 10.1038/s41575-022-00687-7. Epub 2022 Oct 28.

Ulrich Beuers 1, Frank Wolters 2, Ronald P J Oude Elferink 3
 
12.Distinction between Mitochondrial Antibody-Positive and -Negative Primary Biliary Cholangitis
 

Case Rep Gastroenterol. 2023 Jan 6;17(1):14-20. doi: 10.1159/000528437.eCollection 2023 Jan-Dec.

Venkata Vinod Kumar Matli 1, David F Dies 2, Sudha Pandit 3, Gregory Wellman 4, James D Morris 3
 
13.PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
 

J Transl Autoimmun. 2023 Jan 5;6:100188. doi: 10.1016/j.jtauto.2023.100188.eCollection 2023.

Francesca Colapietro 1 2, M Eric Gershwin 3, Ana Lleo 1 2
 
14.Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity
 

Clin Exp Immunol. 2023 Jan 30;uxad012. doi: 10.1093/cei/uxad012. Online ahead of print.

Elvira Favoino 1, Ettore Grapsi 1, Giovanna Barbuti 2, Vasiliki Liakouli 3, Piero Ruscitti 4, Caterina Foti 5, Roberto Giacomelli 6, Federico Perosa 1
 
15.Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis
 

Am J Gastroenterol. 2022 Dec 20. doi: 10.14309/ajg.0000000000002070. Online ahead of print.

Kris V Kowdley 1, Christopher L Bowlus 2, Cynthia Levy 3, Marlyn J Mayo 4, Daniel S Pratt 5, Raj Vuppalanchi 6, Zobair M Younossi 7
 
16.IgG and IgM Immunohistochemistry in Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) Liver Explants
 

Am J Clin Pathol. 2022 Dec 1;158(6):770-773. doi: 10.1093/ajcp/aqac101.

Maylee Hsu 1 2, Jennifer Y Ju 1, Meredith M Pearson 3, Lei Yu 3, Paul E Swanson 1 3, Matthew M Yeh 1 3
 
17.IgG and IgM Immunohistochemistry in Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) Liver Explants
 

Am J Clin Pathol. 2022 Dec 1;158(6):770-773. doi: 10.1093/ajcp/aqac101.

Maylee Hsu 1 2, Jennifer Y Ju 1, Meredith M Pearson 3, Lei Yu 3, Paul E Swanson 1 3, Matthew M Yeh 1 3
 
18.The unhealthy lifestyle in primary biliary cholangitis: An enemy to fight
 

Dig Liver Dis. 2022 Dec 31;S1590-8658(22)00833-7. doi: 10.1016/j.dld.2022.12.009.Online ahead of print.

Valentina Cossiga 1, Nora Cazzagon 2, Roberto Montalti 3, Stefania Ciminnisi 4, Maria Rosaria Attanasio 5, Francesco Pezzato 6, Marco Giacchetto 4, Maria Guarino 5, Vincenza Calvaruso 4, Annarosa Floreani 7, Filomena Morisco 5
 
19.Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
 

Gastroenterology. 2022 Dec;163(6):1630-1642.e3.doi: 10.1053/j.gastro.2022.08.054. Epub 2022 Sep 20.

C Fiorella Murillo Perez 1, Holly Fisher 2, Shaun Hiu 2, Dorcas Kareithi 2, Femi Adekunle 3, Tracy Mayne 3, Elizabeth Malecha 3, Erik Ness 3, Adriaan J van der Meer 4, Willem J Lammers 4, Palak J Trivedi 5, Pier Maria Battezzati 6, Frederik Nevens 7, Kris V Kowdley 8, Tony Bruns 9, Nora Cazzagon 10, Annarosa Floreani 10, Andrew L Mason 11, Albert Parés 12, Maria-Carlota Londoño 12, Pietro Invernizzi 13, Marco Carbone 14, Ana Lleo 15, Marlyn J Mayo 16, George N Dalekos 17, Nikolaos K Gatselis 17, Douglas Thorburn 18, Xavier Verhelst 19, Aliya Gulamhusein 1, Harry L A Janssen 20, Rachel Smith 21, Steve Flack 22, Victoria Mulcahy 22, Michael Trauner 23, Christopher L Bowlus 24, Keith D Lindor 25, Christophe Corpechot 26, David Jones 2, George Mells 27, Gideon M Hirschfield 1, James Wason 28, Bettina E Hansen 29; GLOBAL PBC Study Group and the members of the UK-PBC Consortium

Collaborators

  • GLOBAL PBC Study Group and the members of the UK-PBC Consortium: 

Richard Sturgess, Christopher Healey, Anton Gunasekera, Yiannis Kallis, Gavin Wright, Thiriloganathan Mathialahan, Richard Evans, Jaber Gasem, David Ramanaden, Emma Ward, Mahesh Bhalme, Paul Southern, James Maggs, Mohamed Yousif, George Mells, Brijesh Srivastava, Matthew Foxton, Carole Collins, Yash Prasad, Francisco Porras-Perez, Tom Yapp, Minesh Patel, Roland Ede, Martyn Carte, Konrad Koss, Prayman Sattianayagam, Charles Grimley, Jude Tidbury, Dina Mansour, Matilda Beckley, Coral Hollywood, John Ramag, Harriet Gordon, Joanne Ridpath, Bob Grover, George Abouda, Ian Rees, Mark Narain, Imroz Salam, Paul Banim, Debasish Das, Helen Matthews, Faiyaz Mohammed, Rebecca Jones, Sambit Sen, George Bird, Martin Prince, Geeta Prasad, Paul Kitchen, John Hutchinson, Prakash Gupta, David Jones, Amir Shah, Subrata Saha, Katharine Pollock, Stephen Barclay, Natasha McDonald, Simon Rushbrook, Robert Przemioslo, Andrew Millar, Steven Mitchell, Andrew Davis, Asifabbas Naqvi, Tom Lee, Stephen Ryder, Jane Collier, Matthew Cramp, Richard Aspinal, Jonathan Booth, Earl Williams, Hyder Hussaini, John Christie, Tehreem Chaudhry, Douglas Thorburn, Stephen Mann, Aftab Ala, Julia Maltby, Chris Corbett, Saket Singhal, Barbara Hoeroldt, Jeff Butterworth, Andrew Douglas, Rohit Sinha, Simon Panter, Jeremy Shearman, Gary Bray, Michael Roberts, Daniel Forton, Nicola Taylor, Wisam Jafar, Matthew Cowan, Chin Lye Ch'ng, Mesbah Rahman, Emma Wesley, Sanjiv Jain, Aditya Mandal, Mark Wright, Palak Trivedi, Fiona Gordon, Esther Unitt, Andrew Austin, Altaf Palegwala, Vishwaraj Vemala, Andrew Higham, Jocelyn Fraser, Andy Li, Subramaniam Ramakrishnan, Alistair King, Simon Whalley, Ian Gee, Richard Keld, Helen Fellows, James Gotto, Charles Millson
 
20.Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?
 

Can J Gastroenterol Hepatol. 2022 Dec 6;2022:3618090. doi: 10.1155/2022/3618090.eCollection 2022.

Aaron Wetten 1 2, Laura Ogle 1 2, George Mells 3, Vinod S Hegade 4, Laura Jopson 1 2, Margaret Corrigan 5, Jeremy Palmer 1, Maja Johansson 6, Torbjörn Bäckström 6 7, Magnus Doverskog 6, David E J Jones 1 2, Jessica K Dyson 1 2
 
21.PACK syndrome: A case series and review
 

Am J Med Sci. 2022 Dec 16;S0002-9629(22)00489-X.doi: 10.1016/j.amjms.2022.12.005. Online ahead of print.

B Collins 1, D Dillon 2, R M Silver 2
 
22.Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis
 

Dig Liver Dis. 2022 Dec 31;S1590-8658(22)00834-9. doi: 10.1016/j.dld.2022.12.010.Online ahead of print.

Jakub Gazda 1, Sylvia Drazilova 2, Matej Gazda 3, Martin Janicko 1, Tomas Koky 1, Marian Macej 1, Marco Carbone 4, Peter Jarcuska 1
 
23.Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies
 

Clin Liver Dis. 2022 Nov;26(4):705-726. doi: 10.1016/j.cld.2022.06.012.Epub 2022 Sep 14.

Chung-Heng Liu 1, Christopher L Bowlus 2
 
24.Novel Therapies in Primary Biliary Cholangitis: What Is in the Pipeline?
 

Clin Liver Dis. 2022 Nov;26(4):747-764. doi: 10.1016/j.cld.2022.06.013.Epub 2022 Sep 13.

Keri-Ann Buchanan-Peart 1, Cynthia Levy 2
 
25.Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
 

JHEP Rep. 2022 Jul 21;4(11):100544. doi: 10.1016/j.jhepr.2022.100544. eCollection 2022 Nov.

Christoph Schramm 1 2 3, Heiner Wedemeyer 4, Andrew Mason 5, Gideon M Hirschfield 6, Cynthia Levy 7, Kris V Kowdley 8, Piotr Milkiewicz 9 10, Ewa Janczewska 11 12, Elena Sergeevna Malova 13, Johanne Sanni 14 15, Phillip Koo 16, Jin Chen 16, Subhajit Choudhury 17, Lloyd B Klickstein 18, Michael K Badman 18, David Jones 19
 
26.Contemporary Epidemiology of Primary Biliary Cholangitis
 

Clin Liver Dis. 2022 Nov;26(4):555-570. doi: 10.1016/j.cld.2022.06.001.Epub 2022 Sep 11.

Francesca Colapietro 1, Arianna Bertazzoni 1, Ana Lleo 2
 
27.Liver Transplantation for Primary Biliary Cholangitis
 

Clin Liver Dis. 2022 Nov;26(4):765-781. doi: 10.1016/j.cld.2022.06.014.

Eric F Martin 1
 
28.Hepatocellular Carcinoma in Primary Biliary Cholangitis
 

Clin Liver Dis. 2022 Nov;26(4):691-704. doi: 10.1016/j.cld.2022.06.011.

Alexander M Sy 1, Raphaella D Ferreira 2, Binu V John 2
 
29.Genetics of Primary Biliary Cholangitis
 

Clin Liver Dis. 2022 Nov;26(4):571-582. doi: 10.1016/j.cld.2022.06.002.Epub 2022 Sep 11.

Alessio Gerussi 1, Rosanna Asselta 2, Pietro Invernizzi 3
 
30.Autoantibodies in Primary Biliary Cholangitis
 

Clin Liver Dis. 2022 Nov;26(4):613-627. doi: 10.1016/j.cld.2022.06.004.

Kristel K Leung 1, Gideon M Hirschfield 2
 
31.Primary Biliary Cholangitis in Males: Pathogenesis, Clinical Presentation, and Prognosis
 

Clin Liver Dis. 2022 Nov;26(4):643-655. doi: 10.1016/j.cld.2022.06.008.Epub 2022 Sep 14.

Mina Shaker 1, Natalie Mansour 2, Binu V John 3
 
32.TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation
 

J Hepatol. 2022 Oct;77(4):991-1004. doi: 10.1016/j.jhep.2022.05.044. Epub 2022 Jun 22.

Ibone Labiano 1, Aloña Agirre-Lizaso 1, Paula Olaizola 1, Anne Echebarria 1, Maider Huici-Izagirre 1, Irene Olaizola 1, Aitor Esparza-Baquer 1, Omar Sharif 2, Elizabeth Hijona 3, Piotr Milkiewicz 4, Malgorzata Milkiewicz 5, Francisco González-Romero 6, Patricia Aspichueta 7, Maria J Monte 8, Jose J G Marin 8, Mihael Vucur 9, Tom Luedde 9, Marco Marzioni 10, Derek A Mann 11, Luis Bujanda 12, Pedro M Rodrigues 13, Jesus M Banales 14, Maria J Perugorria 15
 
33.Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)
 

Expert Opin Investig Drugs. 2022 Oct;31(10):1101-1107. doi: 10.1080/13543784.2022.2130750.Epub 2022 Oct 8.

Aaron Wetten 1 2, David Emrys Jeffreys Jones 1 2, Jessica Katharine Dyson 1 2
 
34.Antimitochondrial Antibodies: from Bench to Bedside
 

Clin Rev Allergy Immunol. 2022 Oct;63(2):166-177.doi: 10.1007/s12016-021-08904-y. Epub 2021 Sep 29.

Francesca Colapietro 1 2, Ana Lleo 3 4, Elena Generali 1 2
 
35.Obeticholic Acid for Primary Biliary Cholangitis
 

Biomedicines. 2022 Oct 2;10(10):2464. doi: 10.3390/biomedicines10102464.

Annarosa Floreani 1 2, Daniela Gabbia 3, Sara De Martin 3
 
36.Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases
 

J Hepatol. 2022 Oct 19;S0168-8278(22)03143-9. doi: 10.1016/j.jhep.2022.10.007.Online ahead of print.

Frederik Nevens 1, Michael Trauner 2, Michael P Manns 3
 
37.High Prevalence of Lower Limb Atherosclerosis is Linked with the Gut-Liver-Axis in Patients with Primary Biliary Cholangitis
 

Liver Int. 2022 Oct 26. doi: 10.1111/liv.15463. Online ahead of print.

Francesca Romana Ponziani 1 2, Antonio Nesci 3, Camilla Caputo 1, Lucia Salvatore 1, Anna Picca 4, Federica Del Chierico 5, Francesco Paroni Sterbini 6, Emanuele Marzetti 4, Angela Di Giorgio 3, Luca Santoro 3, Lorenza Putignani 5 7, Antonio Gasbarrini 1 2, Angelo Santoliquido # 3 2, Maurizio Pompili # 1 2
 
38.Alcohol intake is associated with a decreased risk of developing primary biliary cholangitis
 

World J Hepatol. 2022 Sep 27;14(9):1747-1756. doi: 10.4254/wjh.v14.i9.1747.

Janine Adele French 1, Paul Gow 2, Steven Simpson-Yap 3 4, Kate Collins 2, Justin Ng 2, Peter W Angus 2, Ingrid A F van der Mei 4
 
39.UK-wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis
 

Clin Gastroenterol Hepatol. 2022 Aug 9;S1542-3565(22)00738-8.doi: 10.1016/j.cgh.2022.07.038. Online ahead of print.

Nadir Abbas 1, Emma L Culver 2, Douglas Thorburn 3, Neil Halliday 3, Hannah Crothers 4, Jessica K Dyson 5, April Phaw 5, Richard Aspinall 6, Salim I Khakoo 7, Yiannis Kallis 8, Belinda Smith 9, Imran Patanwala 10, Anne McCune 11, Chenchu R Chimakurthi 12, Vinod Hegade 12, Michael Orrell 2, Rebecca Jones 12, George Mells 13, Colette Thain 14, Robert-Mitchell Thain 14, David Jones 5, Gideon Hirschfield 15, Palak J Trivedi 16
 
40.Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
 

Liver Int. 2022 Nov;42(11):2453-2465. doi: 10.1111/liv.15386. Epub 2022 Aug 23.

Antonio De Vincentis 1, Daphne D'Amato 2, Laura Cristoferi 3, Alessio Gerussi 3, Federica Malinverno 3, Ana Lleo 4, Francesca Colapietro 4, Fabio Marra 5, Andrea Galli 6, Cecilia Fiorini 6, Barbara Coco 7, Maurizia Brunetto 7, Grazia Anna Niro 8, Rosa Cotugno 8, Carlo Saitta 9, Raffaele Cozzolongo 10, Francesco Losito 10, Edoardo Giovanni Giannini 11, Sara Labanca 11, Marco Marzioni 12, Giulia Marconi 12, Anna Morgando 2, Rinaldo Pellicano 2, Ester Vanni 2, Nora Cazzagon 13, Annarosa Floreani 13, Luchino Chessa 14, Olivia Morelli 15, Luigi Muratori 16, Adriano Pellicelli 17, Maurizio Pompili 18, Francesca Ponziani 18, Annalisa Tortora 18, Floriano Rosina 19, Maurizio Russello 20, Mariarita Cannavò 20, Loredana Simone 21, Silvia Storato 22, Mauro Viganò 23, Ludovico Abenavoli 24, Maria D'Antò 25, Elisabetta De Gasperi 26, Marco Distefano 27, Gaetano Scifo 27, Teresa Zolfino 28, Vincenza Calvaruso 29, Giuseppe Cuccorese 30, Valeria Pace Palitti 31, Rodolfo Sacco 32, Gaetano Bertino 33, Evelise Frazzetto 33, Domenico Alvaro 34, Giacomo Mulinacci 3, Andrea Palermo 3, Miki Scaravaglio 3, Francesca Terracciani 1, Giovanni Galati 1, Vincenzo Ronca 3, Massimo Zuin 35 36, Ernesto Claar 37, Antonio Izzi 38, Antonio Picardi 1, Pietro Invernizzi 3, Umberto Vespasiani-Gentilucci 1, Marco Carbone 3, on behalf of the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group and, the Italian PBC Registry

 
 
41.Optimization of Laboratory Diagnostics of Primary Biliary Cholangitis: When Solid-Phase Assays and Immunofluorescence Combine
 

 Clin Med. 2022 Sep 5;11(17):5238. doi: 10.3390/jcm11175238.

Federica Gaiani 1 2, Roberta Minerba 3, Alessandra Picanza 3, Annalisa Russo 3, Alessandra Melegari 4, Elena De Santis 4, Tommaso Trenti 5, Lucia Belloni 6, Silvia Peveri 7, Rosalia Aloe 3, Carlo Ferrari 1 8, Luigi Laghi 1 2, Gian Luigi de'Angelis 1 2, Chiara Bonaguri 3
 
42.Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
 

Dig Liver Dis. 2022 Sep;54(9):1215-1221. doi: 10.1016/j.dld.2022.03.002. Epub 2022 Mar 27.

Edoardo G Giannini 1, Giulia Pieri 2, Sara Labanca 2, Maria Corina Plaz Torres 2, Antonio Gasbarrini 3, Elisabetta Biasini 4, Claudia Campani 5, Nora Cazzagon 6, Francesco Giuseppe Foschi 7, Andrea Mega 8, Alberto Masotto 9, Giovanni Raimondo 10, Gian Ludovico Rapaccini 11, Rodolfo Sacco 12, Eugenio Caturelli 13, Maria Guarino 14, Francesco Tovoli 15, Gianpaolo Vidili 16, Maurizia Rossana Brunetto 17, Gerardo Nardone 18, Gianluca Svegliati-Baroni 19, Donatella Magalotti 20, Francesco Azzaroli 21, Giuseppe Cabibbo 22, Maria Di Marco 23, Angelo Sangiovanni 24, Franco Trevisani 25, Italian Liver Cancer (ITA.LI.CA) Study Group
 
43.Longitudinal Assessment of Bile Duct Loss in Primary Biliary Cholangitis
 

Am J Gastroenterol. 2022 Sep 1. doi: 10.14309/ajg.0000000000001985. Online ahead of print.

Julian Hercun 1, Mazen Noureddin 1, Nabil Noureddin 1, Jason Eccleston 1, Daniel Woolridge 1, T Jake Liang 1, Michele Tana 1, David E Kleiner 2, Gracia Viana Rodriguez 1, Christopher Koh 1, Jay H Hoofnagle 1, Theo Heller 1
 
44.Update on the Pharmacological Treatment of Primary Biliary Cholangitis
 

Biomedicines. 2022 Aug 20;10(8):2033. doi: 10.3390/biomedicines10082033.

Annarosa Floreani 1 2, Daniela Gabbia 3, Sara De Martin 3
 
45.Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease
 

Semin Immunopathol. 2022 Jul;44(4):461-474. doi: 10.1007/s00281-022-00940-w.Epub 2022 May 31.

N Richardson 1 2, G E Wootton 3 4, A G Bozward 3 4, Y H Oo 5 6 7 8
 
46.Do Patients with Autoimmune Conditions Have Less Access to Liver Transplantation despite Superior Outcomes?
 

J Pers Med. 2022 Jul 17;12(7):1159. doi: 10.3390/jpm12071159.

Stephanie S Keeling 1, Malcolm F McDonald 2, Adrish Anand 1, Cameron R Goff 1, Caroline R Christmann 1, Spencer C Barrett 1, Michael Kueht 3, John A Goss 4, George Cholankeril 4, Abbas Rana 4
 
47.Individual dynamic prediction of clinical endpoint from large dimensional longitudinal biomarker history: a landmark approach
 

BMC Med Res Methodol. 2022 Jul 11;22(1):188. doi: 10.1186/s12874-022-01660-3.

Anthony Devaux 1, Robin Genuer 2 3, Karine Peres 2, Cécile Proust-Lima 2
 
48.Waitlist mortality in patients with autoimmune liver diseases
 

Ann Hepatol. 2022 Jul 11;100742. doi: 10.1016/j.aohep.2022.100742. Online ahead of print.

Daniela Goyes 1, Romelia Barba 2, Esli Medina-Morales 2, Behnam Saberi 2, Vilas Patwardhan 2, Alan Bonder 3
 
49.How genetic risk contributes to autoimmune liver disease
 

Semin Immunopathol. 2022 Jul;44(4):397-410. doi: 10.1007/s00281-022-00950-8.Epub 2022 Jun 1.

David Ellinghaus 1
 
50.Network Proximity-Based Drug Repurposing Strategy for Early and Late Stages of Primary Biliary Cholangitis
 

Biomedicines. 2022 Jul 13;10(7):1694. doi: 10.3390/biomedicines10071694.

Endrit Shahini 1, Giuseppe Pasculli 2, Andrea Mastropietro 2, Paola Stolfi 3, Paolo Tieri 3, Davide Vergni 3, Raffaele Cozzolongo 1, Francesco Pesce 4, Gianluigi Giannelli 1
 
51.Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
 

J Hepatol. 2022 Jun 28;S0168-8278(22)00411-1. doi: 10.1016/j.jhep.2022.06.017.Online ahead of print.

Christophe Corpechot 1, Fabrice Carrat 2, Farid Gaouar 3, Frederic Chau 2, Gideon Hirschfield 4, Aliya Gulamhusein 4, Aldo J Montano-Loza 5, Ellina Lytvyak 5, Christoph Schramm 6, Albert Pares 7, Ignasi Olivas 7, John E Eaton 8, Karim T Osman 8, George Dalekos 9, Nikolaos Gatselis 9, Frederik Nevens 10, Nora Cazzagon 11, Alessandra Zago 11, Francesco Paolo Russo 11, Nadir Abbas 12, Palak Trivedi 12, Douglas Thorburn 13, Francesca Saffioti 13, Laszlo Barkai 13, Davide Roccarina 13, Vicenza Calvaruso 14, Anna Fichera 14, Adele Delamarre 15, Esli Medina-Morales 16, Alan Bonder 16, Vilas Patwardhan 16, Cristina Rigamonti 17, Marco Carbone 18, Pietro Invernizzi 18, Laura Cristoferi 18, Adriaan van der Meer 19, Rozanne de Veer 19, Ehud Zigmond 20, Eyal Yehezkel 20, Andreas E Kremer 21, Ansgar Deibel 21, Jerome Dumortier 22, Tony Bruns 23, Karsten Große 23, Georges-Philippe Pageaux 24, Aaron Wetten 25, Jessica Dyson 25, David Jones 25, Olivier Chazouilleres 3, Bettina Hansen 4, Victor de Lédinghen 15, Global & ERN Rare-Liver PBC Study Groups
 
52.Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
 

Dig Dis Sci. 2022 Jun 15. doi: 10.1007/s10620-022-07581-x. Online ahead of print.

Marlyn J Mayo 1, Elizabeth Carey 2, Helen T Smith 3, Andrea R Mospan 4, Megan McLaughlin 5, April Thompson 6, Heather L Morris 4, Robert Sandefur 4, W Ray Kim 7, Christopher Bowlus 8, TARGET-PBC Investigators; Cynthia Levy 9
 
53.Clinical Patterns of Primary Biliary Cholangitis: Comparison between Two European case series
 

Rev Recent Clin Trials. 2022 Jun 17. doi: 10.2174/1574887117666220617095856.Online ahead of print.

Ludovico Abenavoli 1, Anna Caterina Procopio 1, Pietro Cinaglia 1, Christian Zanza 2, Claudio Delle Grazie 3, Yaroslava Longhitano 2, Pavla Libicherova 4, Francesco Luzza 1
 
54.The National Audit of Primary Biliary Cholangitis (PBC) in the United Kingdom: Defining the Audit Dataset and Data Collection System
 

Cureus. 2022 Jun 2;14(6):e25609. doi: 10.7759/cureus.25609. eCollection 2022 Jun.

Laura Burke 1, Steve Flack 2, Rebecca Jones 3, Richard J Aspinall 4, Douglas Thorburn 5, David E Jones 6, Conor Braniff 7, Collette Thain 8, Andrew Yeoman 9, Joanna A Leithead 10, Palak J Trivedi 11, George Mells 2, Laith Alrubaiy 12
 
55.Setting Up a Local Registry to Improve the Care of Patients With Primary Biliary Cholangitis
 

Cureus. 2022 May 23;14(5):e25247. doi: 10.7759/cureus.25247. eCollection 2022 May.

Laith Alrubaiy 1, Ceyhun A Oztumer 2
 
56.Portal pressure is of significant prognostic value in primary biliary cholangitis
 

Liver Int. 2022 May 27. doi: 10.1111/liv.15289. Online ahead of print.

Thomas W Warnes 1, Stephen A Roberts 2, Alexander Smith 1, Victor M Cope 3, Patricia Vales 4, Raymond McMahon 5
 
57.The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study
 

EBioMedicine. 2022 May 21;80:104068. doi: 10.1016/j.ebiom.2022.104068. Online ahead of print.

David E J Jones 1, Aaron Wetten 2, Ben Barron-Millar 3, Laura Ogle 3, George Mells 4, Steven Flack 4, Richard Sandford 4, John Kirby 3, Jeremy Palmer 3, Sophie Brotherston 3, Laura Jopson 3, John Brain 3, Graham R Smith 5, Steve Rushton 6, Rebecca Jones 7, Simon Rushbrook 8, Douglas Thorburn 9, Stephen D Ryder 10, Gideon Hirschfield 11, UK-PBC Research Consortium; Jessica K Dyson 2
 
58.High-Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases
 

Hepatol Commun. 2022 May;6(5):965-979. doi: 10.1002/hep4.1871. Epub 2021 Nov 26.

Douglas I Walker # 1, Brian D Juran # 2, Angela C Cheung 3, Erik M Schlicht 2, Yongliang Liang 4, Megan Niedzwiecki 1, Nicholas F LaRusso 2, Gregory J Gores 2, Dean P Jones 4, Gary W Miller 5, Konstantinos N Lazaridis 2
 
59.The Role of Epigenetics in Primary Biliary Cholangitis
 

Int J Mol Sci. 2022 Apr 28;23(9):4873. doi: 10.3390/ijms23094873.

Alessio Gerussi 1 2, Elvezia Maria Paraboschi 3 4, Claudio Cappadona 3 4, Chiara Caime 1 2, Eleonora Binatti 1 2, Laura Cristoferi 1 2, Rosanna Asselta 3 4, Pietro Invernizzi 1 2
 
60.Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis
 

Liver Int. 2022 Feb;42(2):384-393. doi: 10.1111/liv.15079. Epub 2021 Oct 12.

Binu V John 1 2, Bassam Dahman 3, Yangyang Deng 3, Nidah S Khakoo 4, Tamar H Taddei 5 6, David E Kaplan 7 8, Cynthia Levy 2
 
61. Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis
 

Sci Rep. 2022 Feb 22;12(1):3027. doi: 10.1038/s41598-022-06809-0.

Davide Povero # 1, Masahiko Tameda # 2, Akiko Eguchi 2, Wenhua Ren 3, Jihoon Kim 4, Robert Myers 5, Zachary D Goodman 6, Stephen A Harrison 7, Arun J Sanyal 8, Jaime Bosch 9 10, Lucila Ohno-Machado 4, Ariel E Feldstein 11
 
62.Primary biliary cholangitis in pregnancy: A systematic review with meta-analysis
 

Hepatobiliary Pancreat Dis Int. 2022 Mar 10;S1499-3872(22)00023-6.doi: 10.1016/j.hbpd.2022.03.005. Online ahead of print.

Hydar El Jamaly 1, Guy D Eslick 2, Martin Weltman 3
 
63.Primary biliary cholangitis: advances in understanding and management
 

Br J Hosp Med (Lond). 2022 Mar 2;83(3):1-9. doi: 10.12968/hmed.2021.0450.Epub 2022 Mar 24.

Alex Smith 1, Benjamin Giles 1, Richard J Aspinall 1
 
64.A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
 

J Hepatol. 2022 Mar 30;S0168-8278(22)00187-8. doi: 10.1016/j.jhep.2022.02.033.Online ahead of print.

Christopher L Bowlus 1, Michael R Galambos 2, Richard J Aspinall 3, Gideon M Hirschfield 4, David E J Jones 5, Yvonne Dörffel 6, Stuart C Gordon 7, Stephen A Harrison 8, Andreas E Kremer 9, Marlyn J Mayo 10, Paul J Thuluvath 11, Cynthia Levy 12, Mark G Swain 13, Guy W Neff 14, David A Sheridan 15, Carmen M Stanca 16, Christoph P Berg 17, Aparna Goel 18, Mitchell L Shiffman 19, John M Vierling 20, Pol Boudes 21, Alexandra Steinberg 21, Yun-Jung Choi 21, Charles A McWherter 21
 
65.Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
 

Hepatology. 2022 Feb 13. doi: 10.1002/hep.32405. Online ahead of print.

Marlyn J Mayo 1
 
66.Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis
 

Viruses. 2022 Mar 3;14(3):516. doi: 10.3390/v14030516.

Shannon L Turvey 1, Lynora Saxinger 1, Andrew L Mason 2
 
67.Practical management of primary biliary cholangitis
 

Rev Esp Enferm Dig. 2021 Oct 19. doi: 10.17235/reed.2021.8219/2021. Online ahead of print.

Albert Parés 1, Leading PBC Group
 
68.Development of a Theoretically Informed Web-Based Mind-Body Wellness Intervention for Patients With Primary Biliary Cholangitis: Formative Study
 

JMIR Form Res. 2021 Oct 8;5(10):e29064. doi: 10.2196/29064.

Makayla Watt 1, John C Spence 1, Puneeta Tandon 1
 
69.Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis
 

Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426. Online ahead of print.

Surain B Roberts 1 2, Gideon M Hirschfield 1 2, Lawrence J Worobetz 3, Catherine Vincent 4, Jennifer A Flemming 5, Angela Cheung 6, Karim Qumosani 7, Mark Swain 8, Dusanka Grbic 9, Hin Hin Ko 10, Kevork Peltekian 11, Nazia Selzner 12, Lusine Abrahamyan 2 12, Bishoi Aziz 13, Ellina Lytvyak 13, Kattleya Tirona 1, Aliya F Gulamhusein 1 2, Harry LA Janssen 1, Aldo J Montano-Loza 13, Andrew L Mason 13, Bettina E Hansen 1 2, Canadian Network for Autoimmune Liver disease (CaNAL)
 
70.Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma: Analysis of the National Inpatient Sample From 2007 to 2014
 

J Clin Gastroenterol. 2022 Feb 18. doi: 10.1097/MCG.0000000000001675. Online ahead of print.

Daniel D Bodek 1, Matthew M Everwine, Keri E Lunsford, Nneoma Okoronkwo, Pavan A Patel, Nikolaos Pyrsopoulos
 
71.Review of Medical Management of Primary Biliary Cholangitis
 

S D Med. 2021 Dec;74(12):562-568.

Govarthanan Rajendiran 1 2, Charoen Mankongpaisarnrung 1 2, Marco A Olivera-Martinez 3, Timothy M McCashland 4
 
72.Cholestatic Liver Disease and Pregnancy: A Systematic Review and Meta-Analysis
 

J Clin Med. 2022 Feb 18;11(4):1068. doi: 10.3390/jcm11041068.

Bryan Ferrigno 1, Romelia Barba 2, Esli Medina-Morales 2, Hirsh Trivedi 2, Vilas Patwardhan 2, Alan Bonder 2
 
73.Primary biliary cholangitis: review for radiologists
 

Abdom Radiol (NY). 2021 Nov 7. doi: 10.1007/s00261-021-03335-x.Online ahead of print.

Matthew A Morgan 1, Karthik M Sundaram 2
 
74.Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
 

Clin Med. 2022 Jan 28;11(3):681. doi: 10.3390/jcm11030681.

Anne-Christin Beatrice Wilde 1, Lena Maria Greverath 1, Lara Marleen Steinhagen 1, Nina Wald de Chamorro 1, Elise Leicht 1, Janett Fischer 2, Toni Herta 2, Thomas Berg 2, Beate Preuss 3, Reinhild Klein 3, Frank Tacke 1, Tobias Müller 1
 
75.Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation
 

Haematologica. 2021 Sep 1;106(9):2374-2383. doi: 10.3324/haematol.2019.245407.

Pierre-Edouard Debureaux 1, Pierre Bourrier 2, Pierre-Emmanuel Rautou 3, Anne-Marie Zagdanski 2, Morgane De Boutiny 2, Simona Pagliuca 1, Aurélien Sutra Del Galy 1, Marie Robin 1, Régis Peffault de Latour 1, Aurélie Plessier 4, Flore Sicre de Fontbrune 1, Aliénor Xhaard 1, Pedro Henrique de Lima Prata 1, Dominique Valla 3, Gérard Socié 1, David Michonneau 1
 
76.Antibiotic Therapy of 3 Days May Be Sufficient After Biliary Drainage for Acute Cholangitis: A Systematic Review
 

Dig Dis Sci. 2021 Dec;66(12):4128-4139. doi: 10.1007/s10620-020-06820-3.Epub 2021 Jan 19.

Sylke Haal 1 2, Mattheus C B Wielenga 3, Paul Fockens 3, Charlotte A Leseman 3, Cyriel Y Ponsioen 3, Ellert J van Soest 4, Roy L J van Wanrooij 5, Elske Sieswerda 6, Rogier P Voermans 3
 
77.Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium
 

Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e197-e205.doi: 10.1097/MEG.0000000000002011.

Alexandre Pariente 1, Olivier Chazouilleres 2, Xavier Causse 3, Bertrand Hanslik 4, Jean-Pierre Arpurt 5, Jean Henrion 6, Isabelle Rosa 7, Christophe Renou 8, Armand Garioud 9, Christophe Corpechot 2, DESCRIPT and DESCRIPT Study Groups
 
78.Portal hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates
 

Eur J Gastroenterol Hepatol. 2021 Dec 1;33(12):1595-1602.doi: 10.1097/MEG.0000000000002033.

Thomas W Warnes 1, Stephen A Roberts 2, Alexander Smith 1, Victor M Cope 3, Patricia Vales 4, Najib Y Haboubi 5, Raymond F McMahon 6
 
79.Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A Meta-Analysis
 

Liver Transpl. 2021 Jun;27(6):866-875. doi: 10.1002/lt.25935.

Mark R Pedersen 1, Garrett Greenan 2, Sumant Arora 3, Arvind R Murali 3, Marlyn J Mayo 1
 
80.Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy
 

Clin Gastroenterol Hepatol. 2021 Nov;19(11):2241-2251.e1.doi: 10.1016/j.cgh.2020.06.062. Epub 2020 Jul 3.

Aldo J Montano-Loza 1, Christophe Corpechot 2
 
81.Primary biliary cholangitis has the highest waitlist mortality in patients with cirrhosis and acute on chronic liver failure awaiting liver transplant
 

Clin Transplant. 2021 Sep 12;e14479. doi: 10.1111/ctr.14479. 

Ashwani K Singal 1 2, Robert J Wong 3, Rajiv Jalan 4 5, Sumeet Asrani 6, Yong-Fang Kuo 7
 
82.Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis
 

Dig Dis Sci. 2021 Jul;66(7):2439-2451. doi: 10.1007/s10620-020-06498-7.Epub 2020 Aug 2.

Yamini Natarajan 1, Aylin Tansel 2, Parth Patel 2, Kingsley Emologu 2, Richa Shukla 2, Zeeshan Qureshi 2, Hashem B El-Serag 2 3 4 5, Aaron P Thrift 2 5, Fasiha Kanwal 2 3 4 5
 
83.Cost of illness of Primary Biliary Cholangitis - a population-based study
 

Dig Liver Dis. 2021 Sep;53(9):1167-1170. doi: 10.1016/j.dld.2020.07.029. Epub 2020 Aug 21.

Alessio Gerussi 1, Umberto Restelli 2, Davide Croce 3, Marzia Bonfanti 3, Pietro Invernizzi 1, Marco Carbone 4
 
84.Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
 

Hepatol Commun. 2021 May 6;5(8):1426-1436. doi: 10.1002/hep4.1720. eCollection 2021 Aug.

Binu V John 1 2, Kaley Schwartz 1, Cynthia Levy 2, Bassam Dahman 3, Yangyang Deng 3, Paul Martin 2, Tamar H Taddei 4 5, David E Kaplan 6 7
 
85.Long-Term Urinary Copper Excretion on Chelation Therapy in Children with Wilson Disease
 

J Pediatr Gastroenterol Nutr. 2021 Feb 1;72(2):210-215. doi: 10.1097/MPG.0000000000002982.

Atchariya Chanpong 1 2, Anil Dhawan 1
 
86.Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis
 

Hepatology. 2021 Aug;74(2):879-891. doi: 10.1002/hep.31776. Epub 2021 May 26.

Binu V John 1, Gabriella Aitcheson 2, Kaley B Schwartz 1, Nidah S Khakoo 2, Bassam Dahman 3, Yangyang Deng 3, David Goldberg 4, Paul Martin 4, Tamar H Taddei 5 6, Cynthia Levy 4, David E Kaplan 7 8
 
87.Understanding Fatigue in Primary Biliary Cholangitis
 

Dig Dis Sci. 2021 Jul;66(7):2380-2386. doi: 10.1007/s10620-020-06502-0. Epub 2020 Aug 26.

Naw April Phaw 1 2, Jessica Katharine Dyson 1 2, George Mells 3, David Jones 4 5
 
88.Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis
 

Liver Int. 2021 Aug 17. doi: 10.1111/liv.15039. Online ahead of print.

Andreas E Kremer 1 2, Marlyn J Mayo 3, Gideon Hirschfield 4, Cynthia Levy 5, Christopher L Bowlus 6, David E Jones 7, Alexandra Steinberg 8, Charles A McWherter 8, Yun-Jung Choi 8
 
89.Liver stiffness measurements by 2-dimensional shear wave elastography compared to histological and ultrasound parameters in primary biliary cholangitis
 

Scand J Gastroenterol. 2021 Aug 10;1-7.doi: 10.1080/00365521.2021.1928277.Online ahead of print.

Emanuel K Manesis 1, Maria Schina 1, Irene Vafiadis 2, Ilias Gatos 3, John Theotokas 3, Pavlos Zoumpoulis 3, Peter Drazinos 3, John Ketikoglou 1, Ioanna K Delladetsima 4, Dina G Tiniakos 5 6
 
90.The genetic architecture of primary biliary cholangitis
 

Eur J Med Genet. 2021 Jul 23;64(9):104292. doi: 10.1016/j.ejmg.2021.104292.Online ahead of print.

Alessio Gerussi 1, Marco Carbone 2, Cristophe Corpechot 3, Christoph Schramm 4, Rosanna Asselta 5, Pietro Invernizzi 6
 
91.Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
 

Pathologica. 2021 Jun;113(3):170-184. doi: 10.32074/1591-951X-245.

Samantha Sarcognato 1, Diana Sacchi 1, Federica Grillo 2, Nora Cazzagon 3, Luca Fabris 4, Massimiliano Cadamuro 4, Ivana Cataldo 1, Claudia Covelli 5, Alessandra Mangia 6, Maria Guido 1 7
 
92.Recent advances in clinical practice: epidemiology of autoimmune liver diseases
 

Gut. 2021 Jul 15;gutjnl-2020-322362. doi: 10.1136/gutjnl-2020-322362.Online ahead of print.

Palak J Trivedi 1 2 3 4, Gideon M Hirschfield 5
 
93.A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients
 

Expert Rev Gastroenterol Hepatol. 2021 Jul 7;1-11. doi: 10.1080/17474124.2021.1945919.Online ahead of print.

Gideon M Hirschfield 1, Olivier Chazouillères 2, Helena Cortez-Pinto 3, Guilherme Macedo 4, Victor de Lédinghen 5, Femi Adekunle 6, Marco Carbone 7
 
94.Baricitinib and primary biliary cholangitis
 

J Transl Autoimmun. 2021 Jun 1;4:100107. doi: 10.1016/j.jtauto.2021.100107. eCollection 2021.

Stuart C Gordon 1 2, Sheri Trudeau 3, Arie Regev 4, Jonathan M Uhas 1, Sujatro Chakladar 4, Ana Pinto-Correia 4, Klaus Gottlieb 4, Doug Schlichting 4
 
95.Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study
 

Am J Gastroenterol. 2021 Jun 23. doi: 10.14309/ajg.0000000000001343. Online ahead of print.

Anna Reig 1 2, Carmen Álvarez-Navascués 3, Mercedes Vergara 2 4, Elena Gómez-Domínguez 5, Adolfo Gallego-Moya 6, Indhira M Pérez-Medrano 7, Emilio Fábrega 8, Manuel Hernández-Guerra 9, Marina Berenguer 2 10 11, Pamela Estevez 12, Ana Arencibia 13, Rosa M Morillas 2 14, Diana Horta 15, Agustín Albillos 2 16, Marta Casado 17, Gema De la Cruz 18, Eva Fernandez-Bonilla 19, Esther Molina 20, Lander Hijona 21, Moises Diago 22, Conrado M Fernández-Rodriguez 23, Jesús M González-Santiago 24, Margarita Sala 2 25, Judith Gómez-Camarero 26, Manuel Romero-Gomez 2 27, Francisco Suárez 28, Victor Vargas 2 29, Carlos Ferre-Aracil 30, Raúl J Andrade 2 31, Nadia Chahri 32, Albert Parés 1 2

Affi
 
96.The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis
 

Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011. Online ahead of print.

Ben Barron-Millar 1, Laura Ogle 1, George Mells 2, Steven Flack 2, Jonathan Badrock 2, Richard Sandford 2, John Kirby 1, Jeremy Palmer 1, Laura Jopson 1, John Brain 1, Graham R Smith 3, Steve Rushton 4, Vinod S Hegade 5, Rebecca Jones 5, Simon Rushbrook 6, Douglas Thorburn 7, Steve Ryder 8, Gideon Hirschfield 9 10, UK-PBC Research Consortium; Jessica K Dyson 1 11, David Jones 1 11
 
97.An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs
 

Heather J Cordell 1, James J Fryett 1, Kazuko Ueno 2, Rebecca Darlay 1, Yoshihiro Aiba 3, Yuki Hitomi 4, Minae Kawashima 4, Nao Nishida 4, Seik-Soon Khor 2, Olivier Gervais 5, Yosuke Kawai 2, Masao Nagasaki 5, Katsushi Tokunaga 2, Ruqi Tang 6, Yongyong Shi 7, Zhiqiang Li 7, Brian D Juran 8, Elizabeth J Atkinson 9, Alessio Gerussi 10, Marco Carbone 10, Rosanna Asselta 11, Angela Cheung 8, Mariza de Andrade 9, Aris Baras 12, Julie Horowitz 12, Manuel A R Ferreira 12, Dylan Sun 12, David E Jones 13, Steven Flack 14, Ann Spicer 14, Victoria L Mulcahy 14, Jinyoung Byan 15, Younghun Han 15, Richard N Sandford 14, Konstantinos N Lazaridis 8, Christopher I Amos 15, Gideon M Hirschfield 16, Michael F Seldin 17, Pietro Invernizzi 10, Katherine A Siminovitch 18, Xiong Ma 6, Minoru Nakamura 3, George F Mells 19, Canadian PBC Consortium, Chinese PBC Consortium, Italian PBC Study Group, Japan-PBC-GWAS Consortium, US PBC Consortium, and UK-PBC Consortium
 
98.Treatment of primary sclerosing cholangitis
 

Dig Liver Dis. 2021 May 16;S1590-8658(21)00213-9. doi: 10.1016/j.dld.2021.04.028.Online ahead of print.

Annarosa Floreani 1, Sara De Martin 2
 
99.Smoking and Liver Disease
 

Gastroenterol Hepatol (N Y). 2020 Dec;16(12):617-625.

Stephanie M Rutledge 1, Amon Asgharpour
 
100.Identification of a Latitude Gradient in the Prevalence of Primary Biliary Cholangitis
 

Clin Transl Gastroenterol. 2021 May 18;12(5):e00357. doi: 10.14309/ctg.0000000000000357.

Janine French 1, Steve Simpson-Yap 2 3, Ingrid van der Mei 3, Justin Ng 1, Peter Angus 1, Paul J Gow 1
 
101.Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis
 

Am J Gastroenterol. 2021 May 13. doi: 10.14309/ajg.0000000000001280. Online ahead of print.

Binu V John 1, Nidah S Khakoo, Kaley B Schwartz, Gabriella Aitchenson, Cynthia Levy, Bassam Dahman, Yangyang Deng, David S Goldberg, Paul Martin, David E Kaplan, Tamar H Taddei
 
102.Detection of anti-mitochondrial 2-oxoacid dehydrogenase complex subunit's antibodies for the diagnosis of primary biliary cholangitis
 

Clin Immunol. 2021 May 1;108749. doi: 10.1016/j.clim.2021.108749. Online ahead of print.

Elisabet Poyatos 1, Francisco Morandeira 2, Joan Climent 2, Virginia Mas 2, José Castellote 3, Jordi Bas 2
 
103.A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis
 

Am J Gastroenterol. 2021 May 4. doi: 10.14309/ajg.0000000000001285. Online ahead of print.

Jorn C Goet 1, Carla F Murillo Perez, Maren H Harms, Annarosa Floreani, Nora Cazzagon, Tony Bruns, Florian Prechter, George N Dalekos, Xavier Verhelst, Nikolaos K Gatselis, Keith D Lindor, Willem J Lammers, Aliya Gulamhusein, Anna Reig, Marco Carbone, Frederik Nevens, Gideon M Hirschfield, Adriaan J van der Meer, Henk R van Buuren, Bettina E Hansen, Albert Parés, GLOBAL PBC Study Group
 
104.The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
 

J Clin Med. 2021 Apr 18;10(8):1763. doi: 10.3390/jcm10081763.

Marta Mazzetti 1 2, Giulia Marconi 1, Martina Mancinelli 1, Antonio Benedetti 1, Marco Marzioni 1, Luca Maroni 1
 
105.Membranous nephropathy and primary biliary cholangitis: A case report and review of the literature
 

Clin Nephrol. 2021 Apr 26. doi: 10.5414/CN110363. Online ahead of print.

Jonas Zimmermann, Sigrid Harendza, Mercedes Noriega, Linda Reinhard, Elion Hoxha
 
106.Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis
 

J Hepatol. 2021 Apr 18;S0168-8278(21)00245-2. doi: 10.1016/j.jhep.2021.04.010.Online ahead of print.

Atsushi Tanaka 1, Junko Hirohara 2, Toshiaki Nakano 2, Kosuke Matsumoto 3, Olivier Chazouillères 4, Hajime Takikawa 5, Bettina E Hansen 6, Fabrice Carrat 7, Christophe Corpechot 8
 
107.Short Chain Fatty Acid and Fecal Microbiota Profiles Are Linked to Fibrosis in Primary Biliary Cholangitis
 

FEMS Microbiol Lett. 2021 Apr 9;fnab038. doi: 10.1093/femsle/fnab038. Online ahead of print.

Craig Lammert 1, Andrea Shin 1, Huiping Xu 2, Christopher Hemmerich 3, Thomas M O'Connell 4, Naga Chalasani 1
 
108.Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis?
 

J Transl Int Med. 2021 Mar 31;9(1):43-51. doi: 10.2478/jtim-2021-0008. eCollection 2021 Mar.

Panagiotis A Papamichalis 1 2, Kalliopi Zachou 2, Roidoula A Papamichali 1, Maria Ioannou 1, Nikolaos K Gatselis 2, George N Dalekos 2, George K Koukoulis 1
 
109.Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis
 

Aliment Pharmacol Ther. 2021 Mar 25. doi: 10.1111/apt.16336. Online ahead of print.

Pierre-Antoine Soret 1, Laurent Lam 1, Fabrice Carrat 1, Lena Smets 2, Thomas Berg 3, Marco Carbone 4, Pietro Invernizzi 4, Vincent Leroy 5, Palak Trivedi 6, Nora Cazzagon 7, Christina Weiler-Normann 8, Laurent Alric 9, Isabelle Rosa-Hezode 10, Alexandra Heurgué 11, Jean-Paul Cervoni 12, Jérôme Dumortier 13, Pascal Potier 14, Olivier Roux 15, Christine Silvain 16, Christophe Bureau 9, Rodolphe Anty 17, Dominique Larrey 18, Cynthia Levy 19, Albert Pares 20, Christoph Schramm 8, Frederik Nevens 2, Olivier Chazouillères 1, Christophe Corpechot 1
 
110.Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis
 

Aliment Pharmacol Ther. 2021 Mar 25. doi: 10.1111/apt.16336. Online ahead of print.

Pierre-Antoine Soret 1, Laurent Lam 1, Fabrice Carrat 1, Lena Smets 2, Thomas Berg 3, Marco Carbone 4, Pietro Invernizzi 4, Vincent Leroy 5, Palak Trivedi 6, Nora Cazzagon 7, Christina Weiler-Normann 8, Laurent Alric 9, Isabelle Rosa-Hezode 10, Alexandra Heurgué 11, Jean-Paul Cervoni 12, Jérôme Dumortier 13, Pascal Potier 14, Olivier Roux 15, Christine Silvain 16, Christophe Bureau 9, Rodolphe Anty 17, Dominique Larrey 18, Cynthia Levy 19, Albert Pares 20, Christoph Schramm 8, Frederik Nevens 2, Olivier Chazouillères 1, Christophe Corpechot 1
 
111.Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome Triggered by COVID-19
 

Eur J Case Rep Intern Med. 2021 Feb 4;8(3):002264. doi: 10.12890/2021_002264.eCollection 2021.

Balraj Singh 1, Parminder Kaur 2, Michael Maroules 1
 
112.Safety of fibrates in cholestatic liver diseases
 

Liver Int. 2021 Mar 9. doi: 10.1111/liv.14871. Online ahead of print.

Andres F Carrion 1, Keith D Lindor 2, Cynthia Levy 3
 
113.Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach
 

Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810. Online ahead of print.

Laura Cristoferi 1 2 3, Vincenza Calvaruso 4, Diletta Overi 5, Mauro Viganò 6, Cristina Rigamonti 7, Elisabetta Degasperi 8, Vincenzo Cardinale 9, Sara Labanca 10, Nicola Zucchini 11, Anna Fichera 4, Vito Di Marco 4, Monica Leutner 12, Rosanna Venere 13, Antonino Picciotto 10, Martina Lucà 1 2, Giacomo Mulinacci 1 2, Andrea Palermo 1 2, Alessio Gerussi 1 2, Daphne D'Amato 1 2, Sarah Elisabeth O'Donnell 1 2, Federica Cerini 6, Carla De Benedittis 7, Federica Malinverno 1 2, Vincenzo Ronca 1 2, Clara Mancuso 1 2, Nora Cazzagon 14, Antonio Ciaccio 1 2, Donatella Barisani 1, Marco Marzioni 15, Annarosa Floreani 16 17, Domenico Alvaro 9, Eugenio Gaudio 5, Pietro Invernizzi 1 2, Guido Carpino 18, Alessandra Nardi 19, Marco Carbone 1 2, behalf of the Italian PBC Registry
 
114.Real-world experience with obeticholic acid in patients with primary biliary cholangitis
 

JHEP Rep. 2021 Jan 27;3(2):100248. doi: 10.1016/j.jhepr.2021.100248. eCollection 2021 Apr.

Daphne D'Amato 1, Antonio De Vincentis 2, Federica Malinverno 1, Mauro Viganò 3, Domenico Alvaro 4, Maurizio Pompili 5, Antonino Picciotto 6, Valeria Pace Palitti 7, Maurizio Russello 8, Silvia Storato 9, Marie Graciella Pigozzi 10, Vincenza Calvaruso 11, Elisabetta De Gasperi 12, Ana Lleo 13, Antonino Castellaneta 14, Adriano Pellicelli 15, Nora Cazzagon 16, Annarosa Floreani 16, Luigi Muratori 17, Stefano Fagiuoli 18, Grazia Anna Niro 19, Valentina Feletti 20, Raffaele Cozzolongo 21, Natalia Terreni 22, Marco Marzioni 23, Rinaldo Pellicano 24, Pietro Pozzoni 25, Leonardo Baiocchi 26, Luchino Chessa 27, Floriano Rosina 28, Gaetano Bertino 29, Maria Vinci 30, Anna Morgando 24, Ester Vanni 24, Gaetano Scifo 31, Rodolfo Sacco 32, Maria D'Antò 33, Valentina Bellia 34, Roberto Boldizzoni 35, Silvia Casella 36, Barbara Omazzi 37, Guido Poggi 38, Laura Cristoferi 1, Alessio Gerussi 1, Vincenzo Ronca 1, Rosanna Venere 4, Francesca Ponziani 5, Maria Cannavò 8, Alessandro Mussetto 20, Rosanna Fontana 19, Francesco Losito 21, Evelise Frazzetto 29, Marco Distefano 31, Francesca Colapietro 13, Sara Labanca 6, Giulia Marconi 23, Giuseppe Grassi 26, Giovanni Galati 2, Sarah Elizabeth O'Donnell 1, Clara Mancuso 1, Giacomo Mulinacci 1, Andrea Palermo 1, Ernesto Claar 39, Antonio Izzi 40, Antonio Picardi 2, Pietro Invernizzi 1, Marco Carbone 1, Umberto Vespasiani-Gentilucci 2, Italian PBC Registry and the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group
 
115.Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial
 

BMJ Open Gastroenterol. 2021 Mar;8(1):e000579. doi: 10.1136/bmjgast-2020-000579.

Alice Freer 1 2, Felicity Williams 1 3, Simon Durman 4, Jennifer Hayden 2, Palak J Trivedi # 5 2 6, Matthew J Armstrong # 2
 
116.X chromosome contribution to the genetic architecture of primary biliary cholangitis
 

Gastroenterology. 2021 Mar 3;S0016-5085(21)00466-2. doi: 10.1053/j.gastro.2021.02.061.Online ahead of print.

 

Gastroenterology. 2021 Mar 3;S0016-5085(21)00466-2. doi: 10.1053/j.gastro.2021.02.061.Online ahead of print.

Rosanna Asselta 1, Elvezia Maria Paraboschi 1, Alessio Gerussi 2, Heather J Cordell 3, George F Mells 4, Richard N Sandford 4, David E Jones 5, Minoru Nakamura 6, Kazuko Ueno 7, Yuki Hitomi 8, Minae Kawashima 8, Nao Nishida 8, Katsushi Tokunaga 9, Masao Nagasaki 10, Atsushi Tanaka 11, Ruqi Tang 12, Zhiqiang Li 13, Yongyong Shi 13, Xiangdong Liu 14, Ma Xiong 12, Gideon Hirschfield 15, Katherine A Siminovitch 16, Canadian-US PBC Consortium; Italian PBC Genetics Study Group; UK-PBC Consortium; Japan PBC-GWAS Consortium; Marco Carbone 2, Giulia Cardamone 1, Stefano Duga 1, M Eric Gershwin 17, Michael F Seldin 17, Pietro Invernizzi 18
 
117.Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison
 

J Transl Autoimmun. 2021 Jan 6;4:100081. doi: 10.1016/j.jtauto.2021.100081. eCollection 2021.

Lorenzo Montali 1, Andrea Gragnano 1, Massimo Miglioretti 1, Alessandra Frigerio 1, Luca Vecchio 1, Alessio Gerussi 2 3, Laura Cristoferi 2 3, Vincenzo Ronca 2 3, Daphne D'Amato 2 3, Sarah Elizabeth O'Donnell 2 3, Clara Mancuso 2 3, Martina Lucà 2 3, Minami Yagi 4, Anna Reig 5, Laura Jopson 6, Sesé Pilar 5, Dave Jones 6, Albert Pares 5, George Mells 7, Atsushi Tanaka 4, Marco Carbone 2 3, Pietro Invernizzi 2 3
 
118.Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States
 

Hepatol Commun. 2019 Jan 28;3(3):356-364. doi: 10.1002/hep4.1314. eCollection 2019 Mar.

Omer Shahab 1, Mehmet Sayiner 1, James Paik 2, Sean Felix 2, Pegah Golabi 2, Zobair M Younossi 1 2
 
119.Investigational drugs in early phase development for primary biliary cholangitis
 

Expert Opin Investig Drugs. 2021 Feb;30(2):131-141. doi: 10.1080/13543784.2021.1857364.Epub 2020 Dec 11.

Eric M Gochanour 1, Kris V Kowdley 1
 
120.Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis
 

Clin Gastroenterol Hepatol. 2020 Aug 7;S1542-3565(20)31083-1.doi: 10.1016/j.cgh.2020.08.006. Online ahead of print.

Alessio Gerussi 1, Davide Paolo Bernasconi 2, Sarah Elisabeth O'Donnell 1, Willem J Lammers 3, Henk Van Buuren 3, Gideon Hirschfield 4, Harry Janssen 4, Christophe Corpechot 5, Anna Reig 6, Albert Pares 6, Pier Maria Battezzati 7, Massimo Giovanni Zuin 7, Nora Cazzagon 8, Annarosa Floreani 9, Frederik Nevens 10, Nikolaos Gatselis 11, George Dalekos 11, Marlyn J Mayo 12, Douglas Thorburn 13, Tony Bruns 14, Andrew L Mason 15, Xavier Verhelst 16, Kris Kowdley 17, Adriaan van der Meer 3, Grazia Anna Niro 18, Benedetta Terziroli Beretta-Piccoli 19, Marco Marzioni 20, Luca Saverio Belli 21, Fabio Marra 22, Maria Grazia Valsecchi 2, Keith D Lindor 23, Pietro Invernizzi 1, Bettina E Hansen 24, Marco Carbone 25, Italian PBC Study Group and the GLOBAL PBC Study Group
 
121.Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool
 

Eur J Gastroenterol Hepatol. 2020 Dec 14. doi: 10.1097/MEG.0000000000002029.Online ahead of print.

Carla F Murillo Perez 1 2, Aliya Gulamhusein 1, Marco Carbone 3 4, Palak J Trivedi 5, Adriaan J van der Meer 2, Christophe Corpechot 6, Pier Maria Battezzati 7, Willem J Lammers 2, Nora Cazzagon 4 8, Annarosa Floreani 4 8, Albert Parés 9, Frederik Nevens 10, Ana Lleo 11, Marlyn J Mayo 12, Kris V Kowdley 13, Cyriel Y Ponsioen 14, George N Dalekos 15, Nikolaos K Gatselis 15, Douglas Thorburn 16, Andrew L Mason 17, Harry Janssen 1, Xavier Verhelst 4 18, Tony Bruns 19, Keith D Lindor 20, Olivier Chazouillères 6, Pietro Invernizzi 3 4, Bettina E Hansen 1 21, Gideon M Hirschfield 1, GLOBAL PBC Study Group
 
122.Utility of palliative EUS-guided biliary drainage using lumen-apposing metal stents: a prospective multicenter feasibility study (with video)
 

Gastrointest Endosc. 2021 Feb 2;S0016-5107(21)00090-0. doi: 10.1016/j.gie.2021.01.029.Online ahead of print.

Suresh Vasan Venkatachalapathy 1, Martin W James 1, Matthew Huggett 2, Bharat Paranandi 2, Stephen P Pereira 3, Gavin Johnson 4, Aloysious D Aravinthan 5, Guruprasad P Aithal 5
 
123.Is UDCA really a post-transplant panacea?
 

Liver Transpl. 2021 Jan 19. doi: 10.1002/lt.25989. Online ahead of print.

Cynthia Levy 1, Shahnaz Sultan 2
 
124.Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis
 

JHEP Rep. 2020 Nov 4;3(1):100202. doi: 10.1016/j.jhepr.2020.100202. eCollection 2021 Feb.

Jessica Katharine Dyson 1 2, Alasdair Blain 3, Mark David Foster Shirley 4, Mark Hudson 1 2, Steven Rushton 4, David Emrys Jeffreys Jones 1 2
 
125.A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA
 

J Hepatol. 2021 Jan 20;S0168-8278(21)00022-2. doi: 10.1016/j.jhep.2021.01.013.Online ahead of print.

Jörn M Schattenberg 1, Albert Pares 2, Kris V Kowdley 3, Michael A Heneghan 4, Stephen Caldwell 5, Daniel Pratt 6, Alan Bonder 7, Gideon M Hirschfield 8, Cynthia Levy 9, John Vierling 10, David Jones 11, Anne Tailleux 12, Bart Staels 12, Sophie Megnien 13, Remy Hanf 13, David Magrez 13, Pascal Birman 13, Velimir Luketic 14
 
126.Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis
 

J Exp Pharmacol. 2020 Dec 17;12:643-652. doi: 10.2147/JEP.S267375.eCollection 2020.

Annarosa Floreani 1 2
 
127.Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis
 

JHEP Rep. 2020 Sep 29;3(1):100191. doi: 10.1016/j.jhepr.2020.100191. eCollection 2021 Feb.

Maren H Harms 1, Gideon M Hirschfield 2, Annarosa Floreani 3, Marlyn J Mayo 4, Albert Parés 5, Alexander Liberman 6, Elizabeth Smoot Malecha 6, Richard Pencek 6, Leigh MacConell 6, Bettina E Hansen 2 7
 
128.Primary biliary cholangitis
 

Lancet. 2020 Dec 12;396(10266):1915-1926. doi: 10.1016/S0140-6736(20)31607-X.

Ana Lleo 1, Giu-Qiang Wang 2, Merrill Eric Gershwin 3, Gideon M Hirschfield 4
 
129.Portal hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates
 

Eur J Gastroenterol Hepatol. 2020 Dec 14. doi: 10.1097/MEG.0000000000002033.Online ahead of print.

Thomas W Warnes 1, Stephen A Roberts 2, Alexander Smith 1, Victor M Cope 3, Patricia Vales 4, Najib Y Haboubi 5, Raymond F McMahon 6
 
130.UDCA Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis
 

Liver Transpl. 2020 Nov 13. doi: 10.1002/lt.25935. Online ahead of print.

Mark R Pedersen 1, Garrett Greenan 2, Sumant Arora 3, Arvind Murali 3, Marlyn J Mayo 1
 
131.Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review
 

J Clin Transl Hepatol. 2020 Sep 28;8(3):336-346. doi: 10.14218/JCTH.2020.00036.Epub 2020 Aug 24.

Sheena Mago 1, George Y Wu 1
 
132.Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial
 

Gastroenterology. 2020 Oct 5;S0016-5085(20)35226-4. doi:10.1053/j.gastro.2020.10.001.Online ahead of print.

Elsemieke de Vries 1, Ruth Bolier 1, Jorn Goet 2, Albert Parés 3, Jef Verbeek 4, Marleen de Vree 5, Joost Drenth 6, Karel van Erpecum 7, Karin van Nieuwkerk 8, Frans van der Heide 5, Nahid Mostafavi 1, Jeltje Helder 1, Cyriel Ponsioen 1, Ronald Oude Elferink 1, Henk van Buuren 2, Ulrich Beuers 9, Netherlands Association for the Study of the Liver - Cholestasis Working Group
 
133. Genome-wide resolution peripheral blood methylome profiling reveals signatures for cholestatic liver disease
 

Epigenomics. 2020 Aug;12(16):1363-1375. doi: 10.2217/epi-2020-0048. Epub 2020 Sep 11.

Raymond M Moore 1, Zhifu Sun 1, Brian D Juran 2, Konstantinos N Lazaridis 2
 
134.A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA
 

J Hepatol. 2020 Sep 17;S0168-8278(20)33623-0. doi: 10.1016/j.jhep.2020.09.011.Online ahead of print.

G M Hirschfield 1, U Beuers 2, L Kupcinskas 3, P Ott 4, A Bergquist 5, M Färkkilä 6, M P Manns 7, A Parés 8, U Spengler 9, M Stiess 10, R Greinwald 10, M Pröls 10, D Wendum 11, U Drebber 12, R Poupon 13
 
135.Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis
 

J Clin Gastroenterol. 2020 Sep 23. doi: 10.1097/MCG.0000000000001433. Online ahead of print.

Karim T Osman 1, Daniel B Maselli 1, Ilkay S Idilman 2, Daniel J Rowan 3, Jason K Viehman 4, William S Harmsen 4, Denise M Harnois 5, Elizabeth J Carey 6, Andrea A Gossard 1, Nicholas F LaRusso 1, Keith D Lindor 6, Sudhakar K Venkatesh 2, John E Eaton 1
 
136.An update on the management of cholestatic liver diseases
 

Clin Med (Lond). 2020 Sep;20(5):513-516. doi: 10.7861/clinmed.2020-0697.

Gautham Appanna 1, Yiannis Kallis 2
 
137.Review article: pathophysiology and management of primary biliary cholangitis
 

Aliment Pharmacol Ther. 2020 Aug 19. doi: 10.1111/apt.16023. Online ahead of print.

Kristel K Leung 1 2, Maya Deeb 1 2, Gideon M Hirschfield 1 2
 
138.Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis
 

Liver Int. 2020 Aug 25. doi: 10.1111/liv.14645. Online ahead of print.

Emma L Culver 1, Helen K Bungay 2, Margaret Betts 2, Colm Forde 2 3, Otto Buchel 4, Charis Manganis 1, Bryan F Warren 5, Jr Fraser Cummings 1 6, Satish Keshav 1, Simon P L Travis 1, Roger W Chapman 1
 
139.Role of Antinuclear Antibodies in Primary Biliary Cholangitis
 

Am J Gastroenterol. 2020 Jul 22. doi: 10.14309/ajg.0000000000000765. Online ahead of print.

Cynthia Levy 1, Christopher L Bowlus 2
 
140.Reevaluating Goals of Therapy in Primary Biliary Cholangitis: Is Good Enough Is Not Good Enough Anymore?
 

Am J Gastroenterol. 2020 Jul;115(7):1024-1025. doi: 10.14309/ajg.0000000000000693.

Richard J Bower 1, Catherine Frenette 2
 
141.Cholangiocarcinoma: Diagnosis and Management
 

Clin Liver Dis. 2020 Aug;24(3):421-436. doi: 10.1016/j.cld.2020.04.005.Epub 2020 May 29.

Adam P Buckholz 1, Robert S Brown Jr 2
 
142.Gut microbiome in primary sclerosing cholangitis: A review
 

World J Gastroentero. 2020 Jun 7;26(21):2768-2780.doi: 10.3748/wjg.v26.i21.2768.

Rebecca Little 1, Eytan Wine 2, Binita M Kamath 1, Anne M Griffiths 1, Amanda Ricciuto 3
 
143.How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients With Primary Biliary Cholangitis?
 

Digestion. 2020 Jun 3;1-9. doi: 10.1159/000507392. Online ahead of print.

Marcel Vetter 1, Andreas E Kremer 1, Abbas Agaimy 2, Lukas Pfeifer 1, Markus F Neurath 1, Jürgen Siebler 1, Steffen Zopf 3 4
 
144.Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom
 

Clin Gastroenterol Hepatol. 2020 Jun 17;S1542-3565(20)30836-3.doi: 10.1016/j.cgh.2020.06.025. Online ahead of print.

Stephen Rice 1, Viviana Albani 2, Dimitrios Minos 3, Gulnar Fattakhova 2, George F Mells 4, Marco Carbone 4, Steven Flack 4, Nikoletta Varvaropoulou 4, Jonathan Badrock 4, Ann Spicer 4, Richard N Sandford 4, Mark D F Shirley 5, Diarmuid Coughlan 2, Gideon Hirschfield 6, Simon D Taylor-Robinson 7, UK-PBC Consortium; Luke Vale 2, David E J Jones 8
 
145.Risk Factors for Complications After Cholecystectomy for Common Bile Duct Stones: An EAST Multicenter Study
 

Surgery. 2020 Jul;168(1):62-66. doi: 10.1016/j.surg.2020.04.011. Epub 2020 May 26.

Brett M Tracy 1, Cameron W Paterson 2, Denise M Torres 3, Katelyn Young 3, Beth R Hochman 4, Martin D Zielinski 5, Sigrid K Burruss 6, Michelle B Mulder 7, Daniel Dante Yeh 7, Rondi B Gelbard 2, EAST Retained Common Bile Duct Stones Study Group

  • EAST Retained Common Bile Duct Stones Study Group: 

Beth Hochman, Natasha Coleman, Anna Goldenberg-Sandau, Jennifer Schweinsburg, Rondi Gelbard, Cameron Paterson, Brett Tracy, Rondi Gelbard, Cameron Paterson, Brett Tracy, Katelyn Young, Denise Torres, David Morris, Ashley Boyer, Sigrid Burruss, Xian Luo-Owen, Daniel Cullinane, Laura Cullinane, April Mendoza, Apostolos Gaitanidis, Martin Zielinski, Maraya Camazine, Shaneeta Johnson, Michelle Mulder, Rishi Rattan, D Dante Yeh, Jonathan Saxe, Daniel Kinstedt, Amanda Celii, Kiran Venincasa
 
146.Obeticholic Acid-A New Therapy in PBC and NASH
 

B Med Bull. 2020 May 15;133(1):95-104. doi: 10.1093/bmb/ldaa006.

Roger W Chapman 1 2, Kate D Lynch 1 2 3 4
 
147.Emerging Drugs for the Treatment of Primary Biliary Cholangitis
 

Expert Opin Emerg Drugs. 2020 Jun;25(2):101-112. doi: 10.1080/14728214.2020.1751814.Epub 2020 May 5.

Naw April Phaw 1 2, Jessica Katharine Dyson 1 2, David Jones 1 2 3
 
148.Pregnancy Outcomes in Women With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Retrospective Cohort Study
 

BJOG. 2020 Jun;127(7):876-884. doi: 10.1111/1471-0528.16119. Epub 2020 Mar 8.

M Cauldwell 1, F L Mackie 2, P J Steer 1, M A Henehghan 3, J H Baalman 4, J Brennand 5, T Johnston 2, S Dockree 6, C Hedley 7, S Jarvis 8, S Khan 9, F M McAuliffe 4, L Mackillop 6, L Penna 7, B Smith 10, P Trivedi 9, S Verma 11 12, R Westbrook 13, S Winifield 14, C Williamson 15
 
149.Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges
 

Clin Exp Gastroenterol. 2020 Jan 15;13:17-24. doi: 10.2147/CEG.S204638.eCollection 2020.

Hirsh D Trivedi 1, Christopher J Danford 1, Daniela Goyes 1, Alan Bonder 1
 
150.Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase
 

Am J Gastroenterol. 2020 Feb 20. doi: 10.14309/ajg.0000000000000557. Online ahead of print.

Carla F Murillo Perez 1 2, Maren H Harms 2, Keith D Lindor 3, Henk R van Buuren 2, Gideon M Hirschfield 1, Christophe Corpechot 4, Adriaan J van der Meer 2, Jordan J Feld 1, Aliya Gulamhusein 1, Willem J Lammers 2, Cyriel Y Ponsioen 5, Marco Carbone 6, Andrew L Mason 7, Marlyn J Mayo 8, Pietro Invernizzi 6, Pier Maria Battezzati 9, Annarosa Floreani 10, Ana Lleo 11, Frederik Nevens 12, Kris V Kowdley 13, Tony Bruns 14 15, George N Dalekos 16, Nikolaos K Gatselis 16, Douglas Thorburn 17, Palak J Trivedi 18, Xavier Verhelst 19, Albert Parés 20, Harry L A Janssen 1, Bettina E Hansen 1 21, GLOBAL PBC Study Group
 
151.A Clinical Review of Primary Biliary Cholangitis
 

Gastroenterol Nurs. Mar/Apr 2020;43(2):E48-E55. doi: 10.1097/SGA.0000000000000480.

Richard Pullen 1
 
152.Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis
 

Am J Gastroenterol. 2020 Feb;115(2):262-270. doi: 10.14309/ajg.0000000000000512.

Stuart C Gordon 1, Kuan-Han Hank Wu 2, Keith Lindor 3, Christopher L Bowlus 4, Carla V Rodriguez 5 6, Heather Anderson 7, Joseph A Boscarino 8, Sheri Trudeau 2, Loralee B Rupp 9, Irina V Haller 10, Robert J Romanelli 11, Jeffrey J VanWormer 12, Mark A Schmidt 13, Yihe G Daida 14, Amandeep Sahota 15, Jennifer Vincent 16, Talan Zhang 1, Jia Li 1, Mei Lu 1, FOLD Investigators
 
153.Diagnosis and Management of Primary Biliary Cholangitis
 

Am J Gastroenterol. 2019 Jan;114(1):48-63. doi: 10.1038/s41395-018-0390-3.

Zobair M Younossi 1, David Bernstein 2, Mitchell L Shiffman 3, Paul Kwo 4, W Ray Kim 5, Kris V Kowdley 6, Ira M Jacobson 7
 
154.Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing Database
 

Transplantation. 2019 Jun;103(6):1191-1198. doi: 10.1097/TP.0000000000002501.

Amandeep Singh 1, Danielle Fritze 2, Mahsa Mansouri 3, Rocio Lopez 4, Fred Poordad 2 3, Eric Lawitz 2 3, Francisco Cigarroa 2, Glen Halff 2, Naim Alkhouri 3
 
155.Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom
 

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1379-1387.e3. doi: 10.1016/j.cgh.2018.12.007.Epub 2018 Dec 14.

Vinod S Hegade 1, George F Mells 2, Holly Fisher 3, Stuart Kendrick 4, Julia DiBello 5, Kim Gilchrist 5, Graeme J Alexander 2, Gideon M Hirschfield 6, Richard N Sandford 7, David E J Jones 8, UK-PBC Consortium
 
156.Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis
 

Gastroenterol Hepatol. 2019 Sep;17(10):2076-2084.e2. doi: 10.1016/j.cgh.2018.12.028.Epub 2019 Jan 4.

Angela C Cheung 1, Willem J Lammers 2, Carla F Murillo Perez 3, Henk R van Buuren 2, Aliya Gulamhusein 3, Palak J Trivedi 4, Konstantinos N Lazaridis 1, Cyriel Y Ponsioen 5, Annarosa Floreani 6, Gideon M Hirschfield 3, Christophe Corpechot 7, Marlyn J Mayo 8, Pietro Invernizzi 9, Pier Maria Battezzati 10, Albert Parés 11, Frederik Nevens 12, Douglas Thorburn 13, Andrew L Mason 14, Marco Carbone 9, Kris V Kowdley 15, Tony Bruns 16, George N Dalekos 17, Nikolaos K Gatselis 17, Xavier Verhelst 18, Keith D Lindor 19, Ana Lleo 9, Raoul Poupon 7, Harry L A Janssen 3, Bettina E Hansen 20, Global PBC Study Group
 
157.Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use
 

Hepatology. 2019 Jan;69(1):237-244. doi: 10.1002/hep.30174.

Mehmet Sayiner 1 2, Pegah Golabi 1, Maria Stepanova 3, Issah Younossi 3, Fatema Nader 3, Andrei Racila 2 3, Zobair M Younossi 1 2
 
158.Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization
  Sayiner M1,2, Golabi P1, Stepanova M3, Younossi I3, Nader F3, Racila A2,3, Younossi ZM1,2. Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174. [Epub ahead of print]
 
159.Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease
  Mahli A1, Hellerbrand C. Dig Dis. 2016;34 Suppl 1:32-9. doi: 10.1159/000447279. Epub 2016 Aug 22.
 
160.Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
  Lee HW1, Park SY2, Kim SU1, Jang JY3, Park H4, Kim JK1, Lee CK5, Chon YE1, Han KH1. PLoS One. 2016 Jun 10;11(6):e0157358. doi: 10.1371/journal.pone.0157358. eCollection 2016.
 
161.Formulation for Effective Screening and Management of Nonalcoholic Steatohepatitis: Noninvasive NAFLD Management Strategy
  Hirose K1, Kanefuji T2, Suda T2, Sugitani S3, Nagasaki K4, Kubota T5, Igarashi M1, Terai S1. Gastroenterol Res Pract. 2016;2016:6343656. doi: 10.1155/2016/6343656. Epub 2016 Jun 13.
 
162.The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood
  Du S1, Wang C2, Jiang W3, Li C4, Li Y1, Feng R5, Sun C6. Diabetes Res Clin Pract. 2016 Jun;116:183-91. doi: 10.1016/j.diabres.2016.04.047. Epub 2016 Apr 30.
 
163.The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study
  Long MT1,2, Pedley A2,3, Massaro JM2,4, Hoffmann U5, Fox CS2,6. PLoS One. 2016 Jun 24;11(6):e0157517. doi: 10.1371/journal.pone.0157517. eCollection 2016.
 
164.Nonalcoholic fatty liver disease and obstructive sleep apnea
  Aron-Wisnewsky J1, Clement K2, Pépin JL3. Metabolism. 2016 Aug;65(8):1124-35. doi: 10.1016/j.metabol.2016.05.004. Epub 2016 May 13.
 
165.Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis
  Boga S1, Munoz-Abraham AS1, Rodriguez-Davalos MI1, Emre SH1, Jain D1, Schilsky ML1. World J Hepatol. 2016 May 28;8(15):659-64. doi: 10.4254/wjh.v8.i15.659.
 
166.Non-alcoholic fatty liver disease and dyslipidemia: An update
  Katsiki N1, Mikhailidis DP2, Mantzoros CS3.Author information Metabolism. 2016 May 13. pii: S0026-0495(16)30018-X. doi: 10.1016/j.metabol.2016.05.003. [Epub ahead of print]
 
167.The Natural Course of Non-Alcoholic Fatty Liver Disease
  Calzadilla Bertot L1, Adams LA2,3. Int J Mol Sci. 2016 May 20;17(5). pii: E774. doi: 10.3390/ijms17050774.
 
168.Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease
  Hannah WN Jr1, Harrison SA2. Dig Dis Sci. 2016 May;61(5):1365-74. doi: 10.1007/s10620-016-4153-y.
 
169.Gut Microbiota and Lifestyle Interventions in NAFLD
  Houghton D1, Stewart CJ2, Day CP3,4, Trenell M5. Int J Mol Sci. 2016 Mar 25;17(4). pii: E447. doi: 10.3390/ijms17040447.
 
170.A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
  Hossain N1, Kanwar P1, Mohanty SR1. Gastroenterol Res Pract. 2016;2016:7109270. doi: 10.1155/2016/7109270. Epub 2016 Feb 23.
 
171.Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
  Kaswala DH1, Lai M1, Afdhal NH2. Dig Dis Sci. 2016 May;61(5):1356-64. doi: 10.1007/s10620-016-4079-4. Epub 2016 Mar 26.
 
172.Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The
  Ballestri S1, Nascimbeni F2,3, Romagnoli D4, Baldelli E5, Targher G6, Lonardo A7. Int J Mol Sci. 2016 Mar 9;17(3). pii: E355. doi: 10.3390/ijms17030355.
 
173.Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
  Bedossa P1, Patel K2. Gastroenterology. 2016 Mar 19. pii: S0016-5085(16)00354-1. doi: 10.1053/j.gastro.2016.03.008. [Epub ahead of print]
 
174.Telomeres, NAFLD and Chronic Liver Disease
  Donati B1, Valenti L2. Int J Mol Sci. 2016 Mar 15;17(3). pii: E383. doi: 10.3390/ijms17030383.
 
175.Non-alcoholic fatty liver disease and liver transplantation
  Khan RS1, Newsome PN2. Metabolism. 2016 Mar 3. pii: S0026-0495(16)00052-4. doi: 10.1016/j.metabol.2016.02.013. [Epub ahead of print]
 
176.Perspectives on Treatment for Nonalcoholic Steatohepatitis
  Lassailly G1, Caiazzo R2, Pattou F2, Mathurin P3. Gastroenterology. 2016 Mar 10. pii: S0016-5085(16)00323-1. doi: 10.1053/j.gastro.2016.03.004. [Epub ahead of print]
 
177.Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis
  Ergelen R1, Yilmaz Y2, Asedov R3, Celikel C4, Akin H2, Bugdayci O3, Altun E5, Tuney D3. Abdom Radiol (NY). 2016 Mar 10. [Epub ahead of print]
 
178.Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
  Lomonaco R1, Bril F2, Portillo-Sanchez P2, Ortiz-Lopez C3, Orsak B3, Biernacki D2, Lo M4, Suman A5, Weber MH6, Cusi K7. Diabetes Care. 2016 Feb 9. pii: dc151876. [Epub ahead of print]
 
179.Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
  Tapper EB1, Hunink MG2,3, Afdhal NH1, Lai M1, Sengupta N4. PLoS One. 2016 Feb 23;11(2):e0147237. doi: 10.1371/journal.pone.0147237. eCollection 2016.
 
180.Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006
  Shen H1, Liangpunsakul S. J Clin Gastroenterol. 2016 Feb 22. [Epub ahead of print]
 
181.Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease
  Jiang ZG1, Tapper EB1, Connelly MA2, Pimentel CM1, Feldbrügge L1, Kim M3, Krawczyk S3, Afdh Al N1, Robson SC1, Herman M3, Otvos JD2, Mukamal KJ4, Lai M1. Liver Int. 2016 Jan 27. doi: 10.1111/liv.13076. [Epub ahead of print]
 
182.Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis
  Corey KE1,2, Klebanoff MJ3,4, Tramontano AC5, Chung RT6,7, Hur C8,9,10. Dig Dis Sci. 2016 Jan 29. [Epub ahead of print]
 
183.Nonalcoholic Steatohepatitis: Diagnostic Challenges
  Gill RM1, Kakar S2. Surg Pathol Clin. 2013 Jun;6(2):227-57. doi: 10.1016/j.path.2013.03.002. Epub 2013 May 4.
 
184.Is There Any Relation between the Degree of Fatty Liver Disease and Severity of Lower Urinary Tract Symptoms?
  Song YA1, Kwon SS2, Doo SW3, Kim JH4, Yang WJ3, Song YS3. Urology. 2015 Dec 9. pii: S0090-4295(15)01099-7. doi: 10.1016/j.urology.2015.11.030. [Epub ahead of print]
 
185.Circulating microRNAs in nonalcoholic fatty liver disease
  DiStefano JK1, Gerhard GS2. Expert Rev Gastroenterol Hepatol. 2015 Nov 25. [Epub ahead of print]
 
186.Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study
  Piscaglia F1, Svegliati-Baroni G2, Barchetti A3, Pecorelli A1, Marinelli S1, Tiribelli C3,4, Bellentani S3; HCC-NAFLD Italian Study group. Hepatology. 2015 Nov 24. doi: 10.1002/hep.28368. [Epub ahead of print]
 
187.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
  Armstrong MJ1, Gaunt P2, Aithal GP3, Barton D4, Hull D4, Parker R1, Hazlehurst JM5, Guo K4; LEAN trial team, Abouda G6, Aldersley MA7, Stocken D8, Gough SC5, Tomlinson JW5, Brown RM9, Hübscher SG10, Newsome PN11. Lancet. 2015 Nov 19. pii: S0140-6736(15)00803-X. doi: 10.1016/S0140-6736(15)00803-X. [Epub ahead of print]
 
188.Non-alcoholic fatty liver disease and risk of cardiovascular disease
  Lonardo A1, Sookoian S2, Pirola CJ3, Targher G4. Metabolism. 2015 Sep 25. pii: S0026-0495(15)00271-1. doi: 10.1016/j.metabol.2015.09.017. [Epub ahead of print]
 
189.Dietary approach in the treatment of nonalcoholic fatty liver disease
  Ferolla SM1, Silva LC1, Ferrari Mde L1, da Cunha AS1, Martins Fdos S1, Couto CA1, Ferrari TC1. World J Hepatol. 2015 Oct 28;7(24):2522-34. doi: 10.4254/wjh.v7.i24.2522.
 
190.The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis
  Anderson EL1, Howe LD1, Jones HE2, Higgins JP3, Lawlor DA1, Fraser A1. PLoS One. 2015 Oct 29;10(10):e0140908. doi: 10.1371/journal.pone.0140908. eCollection 2015.
 
191.Non-alcoholic Steatohepatitis is Associated with Increased Mortality in Obese Patients Undergoing Bariatric Surgery
  Goossens N1, Hoshida Y2, Song WM3, Jung M4, Morel P4, Nakagawa S5, Zhang B3, Frossard JL6, Spahr L6, Friedman SL5, Negro F7, Rubbia-Brandt L8, Giostra E6. Clin Gastroenterol Hepatol. 2015 Oct 19. pii: S1542-3565(15)01406-8. doi: 10.1016/j.cgh.2015.10.010. [Epub ahead of print]
 
192.Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States
  Singal AK1, Hasanin M, Kaif M, Wiesner R, Kuo YF. Transplantation. 2015 Oct 16. [Epub ahead of print]
 
193.Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
  Nobili V1, Alisi A2, Musso G3, Scorletti E4,5, Calder PC4,5, Byrne CD4,5. Crit Rev Clin Lab Sci. 2015 Oct 14:1-15. [Epub ahead of print]
 
194.Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
  Wood KL1, Miller MH2, Dillon JF2. BMJ Open Gastroenterol. 2015 Feb 17;2(1):e000019. doi: 10.1136/bmjgast-2014-000019. eCollection 2015.
 
195.Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men
  Pramfalk C1, Pavlides M2,3, Banerjee R2, McNeil CA1, Neubauer S2, Karpe F1,4, Hodson L1. J Clin Endocrinol Metab. 2015 Sep 28:jc20152649. [Epub ahead of print]
 
196.Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?
  Tarantino G1, Citro V2, Finelli C3. J Gastrointestin Liver Dis. 2015 Sep;24(3):359-68. doi: 10.15403/jgld.2014.1121.243.gta.
 
197.Nonalcoholic fatty liver disease: Current status and future directions
  Demir M1, Lang S1, Steffen HM1. J Dig Dis. 2015 Sep 25. doi: 10.1111/1751-2980.12291. [Epub ahead of print]
 
198.Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management
  Gracious BL1,2, Bhatt R2,3, Potter C4. J Child Adolesc Psychopharmacol. 2015 Oct 8. [Epub ahead of print]
 
199.Relevance of low testosterone to non-alcoholic fatty liver disease
  Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.
 
200.The Gut Microbiota and Nonalcoholic Fatty Liver Disease
  Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.
 
201.Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
  Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.
 
202.Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
  Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.
 
203.Relevance of low testosterone to non-alcoholic fatty liver disease
  Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.
 
204.The Gut Microbiota and Nonalcoholic Fatty Liver Disease
  Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.
 
205.Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
  Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.
 
206.Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
  Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.
 
207.The Prevalence and Presumed Etiology of Elevated Aminotransferase Levels in a Pacific Northwest Tribal Community
  Scott J, Kowdley KV, Ioannou GN, Krantz E, Lallemand O, Tsosie U, Buchwald D. J Health Care Poor Underserved. 2015;26(3):957-66. doi: 10.1353/hpu.2015.0091.
 
208.Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort
  Pan JJ1, Fisher-Hoch SP1, Chen C1, Feldstein AE1, McCormick JB1, Rahbar MH1, Beretta L1, Fallon MB1. World J Hepatol. 2015 Jun 18;7(11):1586-94. doi: 10.4254/wjh.v7.i11.1586.
 
209.Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease
  Pacana T1, Cazanave S1, Verdianelli A1, Patel V1, Min HK1, Mirshahi F1, Quinlivan E2, Sanyal AJ1. PLoS One. 2015 Aug 31;10(8):e0136822. doi: 10.1371/journal.pone.0136822. eCollection 2015.
 
210.Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography
  Tapper EB1, Sengupta N1, Hunink MG2,3, Afdhal NH1, Lai M1. Am J Gastroenterol. 2015 Sep;110(9):1298-304. doi: 10.1038/ajg.2015.241. Epub 2015 Aug 25.
 
211.Nonmedicinal interventions in nonalcoholic fatty liver disease
  Neuman MG, Nanau RM, Cohen LB. Can J Gastroenterol Hepatol. 2015 Jun-Jul;29(5):241-52.
 
212.Non-alcoholic fatty liver disease following liver transplantation: a clinical review
  Merola J1, Liapakis A2, Mulligan DC1, Yoo PS1. Clin Transplant. 2015 Sep;29(9):728-37. doi: 10.1111/ctr.12585. Epub 2015 Aug 11.
 
213.Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials
  Sato K1, Gosho M2, Yamamoto T3, Kobayashi Y3, Ishii N3, Ohashi T3, Nakade Y3, Ito K3, Fukuzawa Y3, Yoneda M3. Nutrition. 2015 Jul-Aug;31(7-8):923-30. doi: 10.1016/j.nut.2014.11.018. Epub 2014 Dec 24.
 
214.Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
  Buzzetti E1, Lombardi R1, De Luca L1, Tsochatzis EA1. Int J Endocrinol. 2015;2015:343828. doi: 10.1155/2015/343828. Epub 2015 Apr 30.
 
215.Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
  Kohli R1, Myronovych A, Tan BK, Salazar-Gonzalez RM, Miles L, Zhang W, Oehrle M, Sandoval DA, Ryan KK, Seeley RJ, Setchell KD. Dig Dis. 2015;33(3):440-6. doi: 10.1159/000371699. Epub 2015 May 27.
 
216.Trends in the Burden of Non-alcoholic Fatty Liver Disease in a US Cohort of Veterans
  Kanwal F1, Kramer JR2, Duan Z2, Yu X3, White D4, El-Serag HB5. Clin Gastroenterol Hepatol. 2015 Aug 17. pii: S1542-3565(15)01109-X. doi: 10.1016/j.cgh.2015.08.010. [Epub ahead of print]
 
217.Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
  Perumpail RB1, Wong RJ, Ahmed A, Harrison SA.

Dig Dis Sci. 2015 Aug 7. [Epub ahead of print]
 
218.Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
  Vilar-Gomez E1, Martinez-Perez Y2, Calzadilla-Bertot L2, Torres-Gonzalez A2, Gra-Oramas B3, Gonzalez-Fabian L3, Friedman SL4, Diago M5, Romero-Gomez M6.

Gastroenterology. 2015 Aug;149(2):367-378.e5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10.
 
219.Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009
  Younossi ZM1,2,3, Otgonsuren M3, Henry L1,3, Venkatesan C2, Mishra A1, Erario M2, Hunt S1. Hepatology. 2015 Aug 14. doi: 10.1002/hep.28123. [Epub ahead of print]
 
220.NAFLD Review: Diagnosis, Treatment and Outcomes
  Ahmed A1, Wong RJ2, Harrison SA3. Clin Gastroenterol Hepatol. 2015 Jul 27. pii: S1542-3565(15)00988-X. doi: 10.1016/j.cgh.2015.07.029. [Epub ahead of print]
 
 
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2023 GI Fellow Board of Advisors

Other Resources

Journal Abstracts
Hep C Link to Care

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2023 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.